Pharmacopsychiatry 2010; 43(2): 45-49
DOI: 10.1055/s-0029-1237694
Original Paper

© Georg Thieme Verlag KG Stuttgart · New York

Effects of Duloxetine in Treatment-Refractory Men with Posttraumatic Stress Disorder

E. Walderhaug1 , 2 , S. Kasserman2 , D. Aikins1 , 2 , D. Vojvoda2 , C. Nishimura2 , A. Neumeister1 , 2
  • 1Department of Psychiatry, Yale University School of Medicine, West Haven, CT, USA
  • 2National Center for PTSD, Clinical Neurosciences Division, VA Connecticut Healthcare System, West Haven, CT, USA
Further Information

Publication History

received 25.05.2009

revised 13.07.2009 accepted 21.07.2009

Publication Date:
15 December 2009 (eFirst)


Introduction: Although there is evidence that selective serotonin reuptake inhibitors provide some benefit in the treatment of post-traumatic stress disorder (PTSD), most meta-analytical reviews have concluded that effect sizes are small and, moreover, that there may be relatively little benefit for some populations (e. g., combat veterans with co-morbid major depression, MDD). This study aimed to evaluate the effectiveness and tolerability of the dual reuptake inhibitor duloxetine in the treatment of PTSD and co-morbid MDD.

Methods: Twenty-one treatment refractory, male, combat-related patients with PTSD and co-morbid MDD were enrolled in a naturalistic study and twenty completed the trial. Duloxetine was given between 60 and 120 mg daily over 8 weeks.

Results: Duloxetine led to a significant improvement of PTSD-characteristic symptoms as well as co-morbid MDD. Duloxetine effectively reduced nightmares, which is important because decreasing nightmares has been associated with improved sleep in PTSD.

Discussion: The results of this naturalistic study suggest that duloxetine is an effective and well-tolerated treatment for patients with PTSD and co-morbid MDD. These initial results need to be extended to the study of women with PTSD.



A. Neumeister, MD 

Department of Psychiatry

Yale University School of Medicine

VA Connecticut Healthcare System (116-A)

Department of Psychiatry

Clinical Neurosciences Division

950 Campbell Avenue

Bldg. 1, Room 9-174, MSC 151E

West Haven CT 06516


Phone: +1/203/932 5711 ext.: 2428

Fax: +1/203/937 3481